Correctsequence Therapeutics Co., Ltd
Clinical trials sponsored by Correctsequence Therapeutics Co., Ltd, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Gene editing shot aims to tame deadly fat levels in rare disease Results expected Dec 2026 (estimated)
- Gene-Editing breakthrough? new therapy aims to stop sickle cell pain crises Results expected Dec 2026 (estimated)
-
Gene-Editing shot aims to slash dangerous fat levels in blood
Disease control Not yet recruitingThis early study tests a new gene-editing treatment called CS-121 in 15 adults with severe high triglycerides (a type of fat in the blood) that hasn't been controlled by standard treatments. The therapy uses tiny fat particles to deliver a gene editor that targets the APOC3 gene …
Early phase 1 • Sponsor: CorrectSequence Therapeutics Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Gene therapy breakthrough offers hope for Transfusion-Free life in thalassemia
Disease control Not yet recruitingThis study tests a single dose of CS-101, a gene therapy, in 20 people aged 12-35 with β-thalassemia major, a severe blood disorder requiring regular transfusions. The goal is to see if it is safe and can help patients produce enough healthy red blood cells to stop needing transf…
Phase 2 • Sponsor: CorrectSequence Therapeutics Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC